The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

banner

Valeant Pharmaceuticals Enters Into Patent Settlement Agreements with Actavis

13-May-2014 | Source : AG-IP News | Visits : 5945
LAVAL, Quebec - Valeant Pharmaceuticals International Inc. announced in a press release that certain of its subsidiaries have entered into settlement agreements with affiliates of Actavis plc related to Actavis' generic versions of Acanya® Gel, 1.2%/2.5%, and Tiazac ® XC.

Valeant's subsidiaries, Dow Pharmaceuticals Sciences, Inc. and Valeant Pharmaceuticals North America LLC, and Actavis' subsidiary, Watson Laboratories, Inc., entered into an agreement to settle all outstanding patent litigation related to Actavis' generic version of Acanya® (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/2.5%.

Acanya® Gel is a lincosamide antibiotic and benzoyl peroxide indicated for the topical treatment of acne vulgaris.
Under the terms of the agreement, Valeant will grant Actavis a license to market its generic Acanya® Gel beginning July 1, 2018 or earlier under certain circumstances. Other details of the settlement were not disclosed. Launch of Actavis' generic product is contingent upon Actavis receiving final approval from the US Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for generic Acanya® Gel.

Additionally, Valeant's subsidiaries, Valeant Canada L.P. and Valeant International Bermuda, and Actavis Pharma Company have entered into an agreement to settle outstanding patent litigation related to Actavis' generic version of Tiazac ® XC (diltiazem hydrochloride) 180 mg/240mg/300mg/360 mg capsules. Tiazac® XC is a calcium cellular influx inhibitor (slow channel blocker) indicated for treatment of hypertension. It is marketed in Canada by Valeant Canada.

Under the terms of the agreement, which is pending approval from the Federal Court of Canada, it will result in a stay of this application until certain events occur and a dismissal of all remaining proceedings and appeals.
Valeant Pharmaceuticals International, Inc. is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology and branded generics. 
 
 
share



Related Articles